日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

CUHK study to benefit lung cancer patients

Updated: 2011-09-27 06:53

By Fan Feifei(HK Edition)

  Print Mail Large Medium  Small

A study released on Monday by the Chinese University of Hong Kong may mark a significant advance in the treatment of lung cancer.

The study has identified a potential biomarker able to help doctors identify which kinds of lung cancer patients will benefit most from treatment with the pharmaceutical bevacizumab.

The study also established that both high and low doses of bevacizumab are capable of achieving similar outcomes.

Lung cancer is the most common cancer in Hong Kong, and the leading cause of cancer-related deaths.

Bevacizumab effectively attacks the growth of tumor blood vessels.

It was approved as a first-line therapy for advanced lung cancer by the US Food and Drug Administration in 2006.

"Although bevacizumab has become one of the first-line treatments for patients with advanced lung cancer, it is still important to identify the optimal dosage and some certain biomarkers will provide hints," Professor Tony Mok of the university's Department of Clinical Oncology said.

Biomarkers are distinctive biological indicators of a process or condition. Any DNA or protein molecule involved in a biological process can be a potential biomarker, said Mok.

The research, carried out since 2008 by Mok and his team, included studies of 300 patients from different countries, with advanced lung cancer.

The patients were divided into two groups. One group was given bevacizumab in 7.5 mg/kg doses, the other 15 mg/kg. Meanwhile, seven biomarkers - some specific protein closely linked to the inhibition of growth of tumor vessels - were assessed.

The research found that among the seven biomarkers, VEGFA is the most critical biomarker for lung cancer and the patients with low VEGFA levels will benefit most from the bevacizumab treatment.

Professor Tony Mok explained: "VEGFA could serve as a potential biomarker for the identification of suitable patients who may benefit from receiving bevacizumab, and help doctors to tailor treatment regimens after identifying the suitable biomarkers."

The results also indicated that the low dose, at 7.5 mg/kg, has the similar efficacy as 15 mg/kg.

"At present, the bevacizumab treatment is very expensive to common patients and a treatment cycle every three weeks at 7.5 mg/kg costs about HK$15,000 -20,000, and dosages at 15 mg/kg cost around double that," Mok said.

"Thus, the newest finding will save the medical cost for patients since they can achieve the same treatment outcome with half the cost. This significantly improves the cost-effectiveness of treatment," Mok said.

The latest discoveries were unveiled at the 2011 European Multidisciplinary Cancer Congress held in Stockholm, Sweden on Saturday.

fanfeifei@chinadailyhk.com

China Daily

(HK Edition 09/27/2011 page1)

主站蜘蛛池模板: 国产精品一级片 | 欧美特黄aaaaaa | 狠狠干在线观看 | 成人在线免费av | 狠狠操狠狠插 | 色婷婷久久综合久色 | 色婷婷视频在线观看 | 国产精品丝袜在线 | 亚洲成人精品在线观看 | 久久黄色网址 | 在线看日韩av| 日本中文字幕精品 | 中文字幕第69页 | 久久久久久一级片 | 亚洲男人天堂影院 | 日本va欧美va国产激情 | 黄色大视频 | 91九色在线视频 | 日韩在线影视 | 国产手机视频在线 | 特淫毛片 | 日韩一区二区视频在线观看 | 久久精品99国产国产精 | 999在线 | 不卡国产视频 | 中文字幕一二 | 国产午夜在线观看 | 成人午夜在线免费观看 | 新黄色网址 | 精品一区二区三区免费 | 国产成人综合在线 | 国偷自拍第113页 | 国产一区二区三区久久久 | 欧美做受高潮中文字幕 | 欧美日本日韩 | 国产免费黄色片 | 视频一区欧美 | 国产日韩精品视频 | 亚洲一区二区三区影院 | 精品综合久久 | 成年午夜视频 |